

# Niels W C J Van De Donk

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5958490/publications.pdf>

Version: 2024-02-01

133  
papers

9,201  
citations

46984

47  
h-index

43868

91  
g-index

134  
all docs

134  
docs citations

134  
times ranked

7798  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. <i>Blood</i> , 2022, 139, 835-844.	0.6	43
2	CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide. <i>Haematologica</i> , 2022, 107, 437-445.	1.7	63
3	Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. <i>Blood Cancer Journal</i> , 2022, 12, 32.	2.8	73
4	Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. <i>Journal of Clinical Oncology</i> , 2022, 40, 3132-3150.	0.8	13
5	Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands. <i>Blood Cancer Journal</i> , 2022, 12, 41.	2.8	6
6	LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. <i>Leukemia</i> , 2022, 36, 1371-1376.	3.3	81
7	Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). <i>Haematologica</i> , 2021, 106, 1725-1732.	1.7	25
8	Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. <i>Leukemia</i> , 2021, 35, 573-584.	3.3	67
9	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2021, 35, 31-44.	3.3	79
10	Comparison of CD38 antibodies <i>in vitro</i> and <i>ex vivo</i> mechanisms of action in multiple myeloma. <i>Haematologica</i> , 2021, 106, 2004-2008.	1.7	19
11	Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1096.	1.8	25
12	Multiple myeloma. <i>Lancet</i> , The, 2021, 397, 410-427.	6.3	349
13	First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018. <i>Blood Cancer Journal</i> , 2021, 11, 22.	2.8	5
14	Improving the identification of frail elderly newly diagnosed multiple myeloma patients. <i>Leukemia</i> , 2021, 35, 2715-2719.	3.3	5
15	Molecular dynamics of targeting CD38 in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 581-591.	1.2	16
16	Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates. <i>Hemato</i> , 2021, 2, 116-130.	0.2	2
17	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	1.2	67
18	Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study. <i>Haematologica</i> , 2021, 106, 2257-2260.	1.7	22

#	ARTICLE	IF	CITATIONS
19	Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 1571.	1.7	21
20	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	5.1	136
21	Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis. <i>Clinical Cancer Research</i> , 2021, 27, 3793-3803.	3.2	27
22	Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 2196-2215.	2.5	56
23	Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2021, 2, 302-318.	2.6	40
24	Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant. <i>HemaSphere</i> , 2021, 5, e561.	1.2	11
25	European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma. <i>Haematologica</i> , 2021, 106, 2054-2065.	1.7	27
26	The value of bone marrow, liver, and spleen imaging in diagnosis, prognostication, and follow-up monitoring of myeloproliferative neoplasms: a systematic review. <i>Cancer Imaging</i> , 2021, 21, 36.	1.2	3
27	Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients. <i>Cancers</i> , 2021, 13, 2452.	1.7	11
28	CAR T-cell therapy for multiple myeloma: state of the art and prospects. <i>Lancet Haematology</i> , the, 2021, 8, e446-e461.	2.2	75
29	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. <i>Haematologica</i> , 2021, 106, 2799-2812.	1.7	22
30	Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1963-1971.	1.4	14
31	Teclistamab, a B-cell maturation antigen- $\hat{A}$ - $\hat{A}$ CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. <i>Lancet</i> , The, 2021, 398, 665-674.	6.3	138
32	Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2758-2767.	0.8	25
33	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3613-3622.	0.8	25
34	Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy. <i>Advances in Therapy</i> , 2021, 38, 1328-1341.	1.3	2
35	Efficacy and safety of daratumumab combined with all- <i>trans</i> retinoic acid in relapsed/refractory multiple myeloma. <i>Blood Advances</i> , 2021, 5, 5128-5139.	2.5	22
36	Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2021, 10, 4593.	1.0	11

#	ARTICLE	IF	CITATIONS
37	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> , 2021, 8, e934-e946.	2.2	46
38	Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study. <i>Blood Cancer Journal</i> , 2021, 11, 178.	2.8	6
39	Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. <i>Science Translational Medicine</i> , 2021, 13, eabh1962.	5.8	49
40	Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma. <i>Haematologica</i> , 2020, 105, e80-e83.	1.7	12
41	Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. <i>Haematologica</i> , 2020, 105, 1650-1659.	1.7	19
42	Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients. <i>Haematologica</i> , 2020, 105, e302-e306.	1.7	53
43	Immunotherapy in multiple myeloma: when, where, and for who?. <i>Current Opinion in Oncology</i> , 2020, 32, 664-671.	1.1	5
44	Sequencing multiple myeloma therapies with and after antibody therapies. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 248-258.	0.9	10
45	Evidence-Based Minireview: Should all newly diagnosed MM patients receive CD38 antibody-based treatment?. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 259-263.	0.9	6
46	Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment. <i>Frontiers in Oncology</i> , 2020, 10, 1362.	1.3	45
47	Editorial: Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches. <i>Frontiers in Oncology</i> , 2020, 10, 607571.	1.3	0
48	Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell Malignancies. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2089-2104.	1.9	3
49	Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma. <i>HemaSphere</i> , 2020, 4, e413.	1.2	8
50	Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies. <i>Cancers</i> , 2020, 12, 3713.	1.7	23
51	Targeted Therapy With Immunoconjugates for Multiple Myeloma. <i>Frontiers in Immunology</i> , 2020, 11, 1155.	2.2	38
52	Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?. <i>Cells</i> , 2020, 9, 378.	1.8	16
53	Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). <i>Leukemia</i> , 2020, 34, 1840-1852.	3.3	55
54	Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities. <i>Leukemia</i> , 2020, 34, 1964-1966.	3.3	22

#	ARTICLE	IF	CITATIONS
55	Preclinical Activity of JNJ-7957, a Novel BCMA $\alpha$ -CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab. <i>Clinical Cancer Research</i> , 2020, 26, 2203-2215.	3.2	53
56	Resistance Mechanisms towards CD38 $\alpha$ -Directed Antibody Therapy in Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2020, 9, 1195.	1.0	28
57	Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. <i>Haematologica</i> , 2020, 105, 2879-2882.	1.7	20
58	Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. <i>Lancet Haematology</i> , 2020, 7, e447-e455.	2.2	74
59	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). <i>Leukemia</i> , 2020, 34, 2000-2011.	3.3	109
60	A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPCR5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 40-41.	0.6	46
61	T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. <i>Oncotarget</i> , 2020, 11, 4076-4081.	0.8	23
62	Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. <i>Blood</i> , 2019, 134, 668-677.	0.6	87
63	Immunotherapy in myeloma: how far have we come?. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071882266.	1.1	47
64	Reprint of "Immunomodulatory effects of CD38-targeting antibodies". <i>Immunology Letters</i> , 2019, 205, 71-77.	1.1	14
65	Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor $\alpha$ -engineered T Cells. <i>Clinical Cancer Research</i> , 2019, 25, 4014-4025.	3.2	110
66	Insights on Multiple Myeloma Treatment Strategies. <i>HemaSphere</i> , 2019, 3, e163.	1.2	33
67	CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients. <i>Journal of Translational Autoimmunity</i> , 2019, 2, 100022.	2.0	16
68	CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, e100-e103.	1.7	90
69	Oral proteasome inhibitor maintenance for multiple myeloma. <i>Lancet, The</i> , 2019, 393, 204-205.	6.3	4
70	Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e9-e11.	0.2	19
71	High $\alpha$ -Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2019, 95, 279-289.	1.1	117
72	Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2019, 184, 475-479.	1.2	18

#	ARTICLE	IF	CITATIONS
73	Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study. <i>Blood</i> , 2019, 134, 695-695.	0.6	14
74	Efficacy and Safety of Daratumumab Combined with All-Trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma; Results of the Phase 1/2 Dara/ATRA Study. <i>Blood</i> , 2019, 134, 1826-1826.	0.6	7
75	Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study. <i>Blood</i> , 2019, 134, 693-693.	0.6	18
76	Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies. <i>Blood</i> , 2019, 134, 3106-3106.	0.6	14
77	The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma. <i>Blood</i> , 2019, 134, 137-137.	0.6	10
78	The Locomotion Study (MMY4001): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment and Documented Disease Progression. <i>Blood</i> , 2019, 134, 5549-5549.	0.6	1
79	CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 197-206.	1.3	30
80	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2018, 32, 1542-1560.	3.3	68
81	Immunomodulatory effects of CD38-targeting antibodies. <i>Immunology Letters</i> , 2018, 199, 16-22.	1.1	68
82	Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients. <i>Haematologica</i> , 2018, 103, e368-e371.	1.7	43
83	Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update. <i>Drugs</i> , 2018, 78, 19-37.	4.9	108
84	From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. <i>Haematologica</i> , 2018, 103, 197-211.	1.7	110
85	CD38 antibodies in multiple myeloma: back to the future. <i>Blood</i> , 2018, 131, 13-29.	0.6	329
86	Practical Considerations for Antibodies in Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 667-674.	1.8	6
87	CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance. <i>Frontiers in Immunology</i> , 2018, 9, 2134.	2.2	212
88	Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. <i>Lancet Haematology</i> , 2018, 5, e479-e492.	2.2	25
89	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. <i>Haematologica</i> , 2018, 103, 1772-1784.	1.7	86
90	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. <i>Leukemia</i> , 2018, 32, 1883-1898.	3.3	81

#	ARTICLE	IF	CITATIONS
91	Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design. PLoS ONE, 2018, 13, e0197349.	1.1	60
92	Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO).. Journal of Clinical Oncology, 2018, 36, 8013-8013.	0.8	6
93	Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma. Oncotarget, 2018, 9, 33621-33622.	0.8	10
94	Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients. Oncotarget, 2018, 9, 34009-34021.	0.8	17
95	Could daratumumab be used to treat severe allergy?. Journal of Allergy and Clinical Immunology, 2017, 139, 1677-1678.e3.	1.5	8
96	High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation. Haematologica, 2017, 102, 160-167.	1.7	49
97	A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization. Molecular Therapy, 2017, 25, 1946-1958.	3.7	197
98	Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. Clinical Cancer Research, 2017, 23, 7498-7511.	3.2	134
99	Carfilzomib versus bortezomib: no longer an ENDEAVOR. Lancet Oncology, The, 2017, 18, 1288-1290.	5.1	9
100	Primary cardiac lymphoma with central nervous system relapse. Clinical Case Reports (discontinued), 2017, 5, 1454-1458.	0.2	9
101	Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Advances, 2017, 1, 2105-2114.	2.5	155
102	A phase 1/2 study of durvalumab (DURVA) in combination with lenalidomide (LEN) with or without dexamethasone (DEX) in patients (pts) with newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology, 2017, 35, TPS8055-TPS8055.	0.8	1
103	Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica, 2016, 101, 616-625.	1.7	136
104	Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution. European Journal of Haematology, 2016, 97, 479-488.	1.1	15
105	Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. Blood, 2016, 128, 2297-2306.	0.6	49
106	Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. Drugs, 2016, 76, 853-867.	4.9	34
107	Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood, 2016, 127, 681-695.	0.6	179
108	Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood, 2016, 128, 384-394.	0.6	697

#	ARTICLE	IF	CITATIONS
109	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. <i>Blood</i> , 2016, 127, 2955-2962.	0.6	686
110	CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. <i>Blood</i> , 2016, 128, 959-970.	0.6	286
111	Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. <i>International Journal of Laboratory Hematology</i> , 2016, 38, 110-122.	0.7	41
112	Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. <i>Immunological Reviews</i> , 2016, 270, 95-112.	2.8	280
113	Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance. <i>Haematologica</i> , 2016, 101, e339-e342.	1.7	34
114	Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA). <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1105-9.	1.4	65
115	A phase 1b study of durvalumab (MEDI4736) alone or in combination with pomalidomide (POM) with or without low dose-dexamethasone (LoDEX) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS8072-TPS8072.	0.8	2
116	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. <i>Haematologica</i> , 2015, 100, 263-268.	1.7	96
117	Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 373, 1207-1219.	13.9	948
118	Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib. <i>Clinical Cancer Research</i> , 2015, 21, 2802-2810.	3.2	136
119	Monoclonal antibodies in myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 599-609.	0.3	26
120	The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. <i>Haematologica</i> , 2014, 99, 984-996.	1.7	124
121	Diagnosis and Risk Stratification in Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 791-813.	0.9	19
122	Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma. <i>Haematologica</i> , 2014, 99, 1846-1853.	1.7	17
123	Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance. <i>Clinical Cancer Research</i> , 2013, 19, 5591-5601.	3.2	48
124	Treatment of relapsed and refractory multiple myeloma in the era of novel agents. <i>Cancer Treatment Reviews</i> , 2011, 37, 266-283.	3.4	66
125	Staphylococcus aureus pericardial abscess presenting as a localized bulge of the heart contour. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2010, 10, 818-819.	0.5	4
126	Acute and chronic renal artery stenosis. <i>European Heart Journal</i> , 2010, 31, 14-14.	1.0	1



#	ARTICLE	IF	CITATIONS
127	New Treatment Strategies for Multiple Myeloma by Targeting BCL-2 and the Mevalonate Pathway. <i>Current Pharmaceutical Design</i> , 2006, 12, 327-340.	0.9	31
128	A Novel In Vivo Animal Model for Human Multiple Myeloma Based on Bioluminescence Imaging of Tumor Cell Growth.. <i>Blood</i> , 2005, 106, 3452-3452.	0.6	2
129	Geranylgeranylated proteins are involved in the regulation of myeloma cell growth. <i>Clinical Cancer Research</i> , 2005, 11, 429-39.	3.2	19
130	The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. <i>Blood</i> , 2004, 103, 4362-4364.	0.6	171
131	A Phase I Trial of Dose Escalating Simvastatin Combined with Chemotherapy in End-Stage Myeloma and Lymphoma.. <i>Blood</i> , 2004, 104, 3458-3458.	0.6	0
132	Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. <i>Blood</i> , 2003, 102, 3354-3362.	0.6	114
133	Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells. <i>Clinical Cancer Research</i> , 2003, 9, 5735-48.	3.2	39